Critical Comparison: Ultragenyx Pharmaceutical (NASDAQ:RARE) & Immunome (NASDAQ:IMNM)
by Jessica Moore · The Cerbat GemUltragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) and Immunome (NASDAQ:IMNM – Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.
Insider & Institutional Ownership
97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. Comparatively, 44.6% of Immunome shares are owned by institutional investors. 5.2% of Ultragenyx Pharmaceutical shares are owned by insiders. Comparatively, 7.2% of Immunome shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Risk and Volatility
Ultragenyx Pharmaceutical has a beta of 0.31, meaning that its share price is 69% less volatile than the S&P 500. Comparatively, Immunome has a beta of 2.13, meaning that its share price is 113% more volatile than the S&P 500.
Profitability
This table compares Ultragenyx Pharmaceutical and Immunome’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Ultragenyx Pharmaceutical | -81.79% | -1,024.42% | -44.40% |
| Immunome | N/A | -50.56% | -46.93% |
Valuation & Earnings
This table compares Ultragenyx Pharmaceutical and Immunome”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Ultragenyx Pharmaceutical | $673.00 million | 2.04 | -$575.00 million | ($5.84) | -2.39 |
| Immunome | $6.94 million | 406.86 | -$212.39 million | ($2.53) | -9.83 |
Immunome has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. Immunome is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of current ratings for Ultragenyx Pharmaceutical and Immunome, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ultragenyx Pharmaceutical | 1 | 9 | 10 | 1 | 2.52 |
| Immunome | 1 | 0 | 12 | 0 | 2.85 |
Ultragenyx Pharmaceutical presently has a consensus price target of $36.63, suggesting a potential upside of 162.89%. Immunome has a consensus price target of $34.64, suggesting a potential upside of 39.33%. Given Ultragenyx Pharmaceutical’s higher probable upside, equities analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Immunome.
Summary
Immunome beats Ultragenyx Pharmaceutical on 9 of the 15 factors compared between the two stocks.
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.
About Immunome
Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.